 |
|
|
| |
Activity of Dolutegravir (DTG) 50 mg BID vs Placebo (PBO) Over 7 Days of Functional Monotherapy in Patients Harbouring Raltegravir- and/or Elvitegravir-Resistant Virus: Primary Endpoint Results of the VIKING-4 Study (ING116529)
|
| |
| |
Reported by Jules Levin
14th European AIDS Conference Oct 16-19 2013 Brussels, Belgium
B Akil,1 G Blick,2 D Hagins,3 M Ramgopal,4 G Richmond,5 R Samuel,6 N Givens,7 C Vavro,8 B Wynne,9 M Ait-Khaled,7 for the VIKING-4 study team
1Chelsea Village Medical, PC, New York, NY, USA; 2CIRCLE CARE Center, Norwalk, CT, USA; 3Chatham County Health Department, Savannah, GA, USA; 4Midway Immunology and Research Center, Fort Pierce, FL, USA; 5Gary J. Richmond, MD, PA, Fort Lauderdale, FL, USA; 6Temple University, Philadelphia, PA, USA; 7-9GlaxoSmithKline, 7London, UK; 8Research Triangle Park, NC, USA; 9Philadelphia, PA, USA
|
| |
|
|
|
|
|
